All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-19T12:41:48.000Z

UCB-derived platelet gel for the treatment of skin ulcers in pediatric patients with cGvHD: Results from a randomized trial

Jun 19, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic GvHD.


Results from a randomized clinical trial assessing the safety and efficacy of allogeneic umbilical cord blood (UCB)-derived platelet gel for the management of skin ulcers in pediatric patients with chronic graft-versus-host disease (cGvHD) were published in Transplantation and Cellular Therapy by Mohseni et al.1 Two ulcers per patient, with similar size and depth, and located symmetrically or near-symmetrically on body areas, were treated with either conventional or platelet gel (a platelet-rich plasma derived product)-containing dressings, in 16 patients aged 5–15 years old.1


Key learnings:

UCB-derived platelet gels improved healing in pediatric patients with cGvHD-related refractory skin ulcers, with significant reductions in wound surface area by Day 15; six vs zero ulcers healed in the treatment vs control group by the end of the study, and a greater proportion of ulcers exhibited a >50% reduction in size (87.5% vs 6.25%; p < 0.01).

No infections, allergic reactions, or increased pain were reported in either group.

This suggests that UCB-derived platelet gels could be a viable and safe therapeutic option for managing refractory skin ulcers in cGvHD, a condition with limited effective treatments, improving patient outcomes and quality of life.

Further research is needed to compare the efficacy of different platelet gel preparations and their combination with other therapies, such as mesenchymal stem cells, and to explore applications in ocular, mucosal, and acute skin GvHD.


  1. Mohseni R, Mahdavi Sharif P, Khosravi A, et al. The application of umbilical cord blood-derived platelet gel for skin ulcers associated with chronic graft-versus-host disease in pediatrics: A randomized trial.Transplant Cell Ther. 2024;24:S2666-6367(24)00366-X. DOI:1016/j.jtct.2024.04.013

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox